Review: Senescent renal tubular cells in diabetic kidney disease and candidate interventions
This review describes how senescence of renal tubular epithelial cells is linked to early diabetic kidney disease and progressive scarring, and briefly surveys potential therapies such as SGLT2 inhibitors, metformin, mesenchymal stem cell therapy and natural products. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that current standard treatment can slow diabetic kidney disease but cannot reverse progressive structural kidney damage. [1]
According to the review, senescence of renal tubular epithelial cells is a central feature of early-stage diabetic kidney disease and a key mechanism driving fibrosis and kidney function decline. [1]
The review briefly covers research progress and clinical limitations of SGLT2 inhibitors, metformin, mesenchymal stem cell therapy and potential natural products as strategies to delay or eliminate senescent cells. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Renal tubular epithelial cells in the diabetic kidney microenvironment, discussed in a review of diabetic kidney disease
- Summary based on
- Study abstract
- Original publication
- September 21, 2026
Senescent tubular cells in early diabetic kidney disease
The review states that diabetic kidney disease is a leading cause of end-stage kidney disease. Current standard treatment can slow progression but cannot reverse progressive structural kidney damage. According to the review, emerging evidence indicates that senescence of renal tubular epithelial cells is a central feature of early-stage disease and a key mechanism driving renal interstitial fibrosis and progressive decline in kidney function.
Supporting source [1]
Molecular networks the review links to tubular senescence
The review systematically describes emerging molecular networks governing tubular epithelial cell senescence in the diabetic kidney microenvironment. It explores roles of glucolipotoxicity from metabolic dysregulation, persistent reactive oxygen species stress, DNA damage, paracrine toxicity mediated by the senescence-associated secretory phenotype, abnormal epigenetic modifications, and failure of endogenous protective mechanisms such as mitophagy.
Supporting source [1]
Brief survey of candidate senescent-cell strategies
The review gives a brief overview of current potential strategies to delay or eliminate senescent cells. It covers research progress and clinical limitations related to sodium-glucose cotransporter 2 inhibitors, metformin, mesenchymal stem cell therapy and potential natural products. These are described as potential strategies, not as established treatments.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no study design, sample, follow-up or outcome data, and the therapeutic strategies are described only as potential, with clinical limitations noted but not detailed.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Shi J, Sun J, Gao J, Luo J, Dai Y, Hua S, Wu C, Wang L, Liu P. · europepmc.org · September 21, 2026